PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis

Claudia Augello, Umberto Gianelli, Rossella Falcone, Silvia Tabano, Federica Savi, Eleonora Bonaparte, Michele Ciboddo, Leda Paganini, Antonina Parafioriti, Dario Ricca, Silvia Lonati, Daniele Cattaneo, Nicola Stefano Fracchiolla, Alessandra Iurlo, Agostino Cortelezzi, Silvano Bosari, Monica Miozzo, Silvia Maria Sirchia

Research output: Contribution to journalArticlepeer-review


Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterised by the clonal proliferation of the haematopoietic precursors together with the progressive development of bone marrow fibrosis. This stromal alteration is an important clinical issue and specific prognostic markers are not currently available. In bone marrow biopsies from 58 PMF patients, we explored the methylation pattern of genes encoding cytokines involved in the stromal reaction, namely platelet-derived growth factor-beta (PDGFB), transforming growth factor-beta (TGFB) and basic fibroblast growth factor (FGF2). We also evaluated the methylation profile of the Long Interspersed Nucleotide Element 1 (LINE-1). PDGFB, FGF2 and LINE-1, but not TGFB, were significantly differently methylated in PMF compared to controls. Significantly, PDGFB hypomethylation (

Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalLeukemia Research
Issue number2
Publication statusPublished - Feb 1 2015


  • DNA methylation
  • FGF2
  • LINE-1
  • Primary myelofibrosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)


Dive into the research topics of 'PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis'. Together they form a unique fingerprint.

Cite this